Shorter Overall Survival (OS) in HER2-positlve (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) ± chemotherapy (CT) and overexpressing HER3 by immunohistochemistry (IHC)

被引：0
|
作者：
Gori, S.
Sidoni, A. [2 ]
Colozza, M.
Mameli, M. G. [2 ]
Fenocchio, D. [1 ]
Minenza, E.
Foglietta, J.
Stocchi, L.
De Angelis, V. [3 ]
Crino, L.
机构：
[1] Santa Maria Misericordia Hosp, Pathol Anat & Histol Serv, Perugia, Italy
[2] Univ Perugia, Inst Pathol Anat & Histol, I-06100 Perugia, Italy
[3] ASL2 Perugia, Palliat Cure Serv, Perugia, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70981-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：287 / 287
页数：1
相关论文
共 50 条
  • [1] HER3 STATUS BY IMMUNOHISTOCHEMISTRY (IHC) IN HER2-POSITIVE (HER2+) METASTATIC BREAST CANCER (MBC) PATIENTS (PTS) TREATED WITH TRASTUZUMAB (T) ± CHEMOTHERAPY (CT): CORRELATION WITH CLINICAL OUTCOME
    Gori, Stefania
    Sidoni, Angelo
    Colozza, Mariantonietta
    Mameli, Maria Grazia
    Fenocchio, Daniela
    Minenza, Elisa
    Foglietta, Jennifer
    Stocchi, Lucia
    De Angelis, Verena
    Crino, Lucio
    ANNALS OF ONCOLOGY, 2009, 20
  • [2] PTEN, EGFR, MAPK and Akt status by immunohistochemistry (IHC) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) ± chemotherapy (CT):: correlation with clinical outcome
    Gori, S.
    De Angelis, V.
    Sidoni, A.
    Colozza, M.
    Ferri, I.
    Fenocchio, D.
    Ludovini, V.
    Basurto, C.
    Anastasi, R.
    Crino, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 223 - 223
  • [3] EGFR, MAPK, AKT and PTEN status by immunohistochemistry (IHC):: Correlation with clinical outcome in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (PTS) treated with trastuzumab (T) ± chemotherapy (CT)
    Gori, Stefania
    De Angelis, Verena
    Sidoni, Angelo
    Colozza, Mariantonietta
    Ferri, Ivana
    Fenocchio, Daniela
    Ludovini, Vienna
    Basurto, Carlo
    Anastasi, Paola
    Crino, Lucio
    ANNALS OF ONCOLOGY, 2007, 18 : 52 - 52
  • [4] EGFR, MAPK, and Akt status by immunohistochemistry (IHC) are not correlated with clinical outcome in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) with or without chemotherapy (CT)
    Gori, S.
    Sidoni, A.
    Colozza, M.
    Ferri, I.
    Cioccoloni, C.
    Fenocchio, D.
    Mosconi, A.
    Anastasi, P.
    De Angelis, V.
    Crino, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).
    Berghoff, A.
    Bartsch, R.
    Bago-Horvath, Z.
    Dubsky, P. C.
    Rudas, M.
    Pluschnig, U.
    Wiltschke, C.
    Gnant, M.
    Steger, G. G.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).
    Bartsch, R.
    Berghoff, A.
    Pluschnig, U.
    Bago-Horvath, Z.
    Dubsky, P. C.
    Rottenfusser, A.
    Wenzel, C.
    Rudas, M.
    Fitzal, F.
    Dieckmann, K.
    Gnant, M.
    Zielinski, C.
    Steger, G. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] High incidence of brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) treated with trastuzumab and chemotherapy
    Gori, S.
    Rimondini, S.
    De Angelis, V.
    Sidoni, A.
    Mosconi, A. M.
    Aristei, C.
    Franceschi, E.
    Esposti, R. Degli
    Colozza, M.
    Crino, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 115 - 116
  • [8] Outcome of HER2-Positive (HER2+) Metastatic Breast Cancer Patients (MBC) Treated with Trastuzumab (T): An Institutional Based Review
    Guilhaume, M-N
    Dieras, V
    Fall, M.
    Pierga, J-Y
    Beuzeboc, P.
    Cottu, P. H.
    Simondi, C.
    Courbard, M.
    Mignot, L.
    Livartowski, A.
    CANCER RESEARCH, 2009, 69 (24) : 801S - 801S
  • [9] Clinical factors associated with overall survival (OS) for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) treated with HER2-targeting systemic therapy (HER2Tx)
    Gullo, G.
    Walsh, N.
    Zacchia, A.
    Hammond, L.
    Fennelly, D.
    Walshe, J.
    O'Mahony, K.
    Maltese, M.
    Crown, J.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S44 - S44
  • [10] THE ROLE OF HER3 EXPRESSION AND PTEN LOSS IN PATIENTS WITH HER2-OVEREXPRESSING METASTATIC BREAST CANCER (MBC)
    Park, Y. H.
    Jung, H. A.
    Choi, Y. L.
    Do, I. -G.
    Ahn, J. -S.
    Im, Y. -H.
    ANNALS OF ONCOLOGY, 2013, 24
12345